Non-Regulatory

December 1, 2017

Bästa aktieägare i Affibody Medical AB

Vid extra bolagsstämma i bolaget den 23 november i år beslöts att genomföra en nyemission av aktier i bolaget.

Read more

Non-Regulatory

November 17, 2017

Interim Report – January to September 2017

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

November 8, 2017

Kallelse till extra bolagsstämma

Aktieägarna i Affibody Medical AB (publ) kallas härmed till extra bolagsstämma torsdagen den 23 november 2017 kl 16.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.

Read more

Non-Regulatory

September 6, 2017

Affibody Announces Presentation of Interim Data from Phase I/II Clinical Trial of ABY-035 at European Academy of Dermatology and Venereology

Solna, Sweden, September 6, 2017. Affibody AB (“Affibody”), a clinical stage next generation biopharmaceutical company developing a portfolio of innovative drug projects, today announced that interim data from the...

Read more

Non-Regulatory

August 23, 2017

Interim Report – January to June 2017

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

May 24, 2017

Kallelse till årsstämma

Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma torsdagen den 29 juni 2017 klockan 13.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.

Read more

Non-Regulatory

May 19, 2017

Interim Report – January to March 2017

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued...

Read more

Non-Regulatory

May 10, 2017

Affibody To Initiate Phase II Psoriasis Trials For Lead Candidate ABY-035

Solna, Sweden, May 10, 2017. Affibody AB (“Affibody”) today announced that it has decided to initiate Phase II development with ABY-035, which is the company’s proprietary psoriasis program.

Read more

Non-Regulatory

February 24, 2017

Year End Report 2016

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more